A study investigated the safety and efficacy of autologous stem-cell transplantation (ASCT) in combination with anti-CD30 chimeric antigen receptor (CAR30) T-cell infusion for relapsed/refractory CD30 + lymphoma. This evidence concerns the gene TNFRSF8 and lymphoma.